Meeting NewsVideo

VIDEO: ROCKET 2 demonstrates comparable efficacy of Rhopressa, timolol

HONOLULU — The ROCKET 2 trial found once-daily treatment with Aerie Pharmaceuticals’ Rhopressa (netarsudil ophthalmic solution 0.02%) to be comparable with twice-daily treatment with timolol maleate 0.05% while maintaining a similar side effect profile, Janet B. Serle, MD, said at the Association for Research in Vision and Ophthalmology meeting here.

HONOLULU — The ROCKET 2 trial found once-daily treatment with Aerie Pharmaceuticals’ Rhopressa (netarsudil ophthalmic solution 0.02%) to be comparable with twice-daily treatment with timolol maleate 0.05% while maintaining a similar side effect profile, Janet B. Serle, MD, said at the Association for Research in Vision and Ophthalmology meeting here.

    See more from Association for Research in Vision and Ophthalmology